Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KROS

+ Watchlist+ Portfolio

Keros Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$11.39
52-Week Range
$8.98 – $22.55
Market Cap
$217.44M
P/E (TTM)
—
EPS (TTM)
-2.32
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.79
PEG Ratio
—
Return on Equity
-12.56%
Return on Assets
-8.36%
Gross Margin
-82.36%
Operating Margin
-172.38%
Profit Margin
-151.43%
Current Ratio
18.14
Debt/Equity
0.05
Total Debt
$15.11M
Free Cash Flow
$-30.61M
Revenue Growth
180.50%
Earnings Growth
—
Enterprise Value
$-26.92M

Market Snapshot

About

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead programs target hematologic and musculoskeletal disorders including myelodysplastic syndromes, pulmonary arterial hypertension, and fibrodysplasia ossificans progressiva. Keros leverages its expertise in TGF-beta biology to develop therapeutics addressing significant unmet medical needs.